Phase II Trial of RAD001 in Refractory Colorectal Cancer

Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00337545

Enrollment

Registered

2006-06-16

Start date

2006-05-31

Completion date

2007-04-30

Last updated

2007-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Metastatic, Refractory

Brief summary

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Detailed description

Study is completed and closed.

Interventions

DRUGRAD001

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens * Measurable disease * ECOG 0-2

Exclusion criteria

* CNS disease * Chemotherapy or radiotherapy \< 4 weeks prior * Active bleeding diathesis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026